Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669561 · ClinicalTrials.gov registry record · Phase 4
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
A Phase 4 study of Dry Eye, sponsored by Research Insight.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT04669561: Completed Phase 4 study of Dry Eye, sponsored by Research Insight.
NCT04669561 is a Phase 4 study of Dry Eye that has completed, run by Research Insight. The registered enrollment target is 100 participants, roughly in line with the 93-participant average among 41 other Dry Eye trials with a reported enrollment target. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669561, a Phase 4 study of Dry Eye, has completed, sponsored by Research Insight.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.
Primary Outcome
Change in corneal higher order aberrations after 7, 14, and 28 days of treatment.
Conditions Studied
Interventions
- DRUG Lifitegrast 5% Ophthalmic Solution
Study Locations (3)
California
- Harvard Eye Associates - Laguna Hills
Florida
- Bowden Eye & Associates - Jacksonville
Ohio
- Cleveland Eye Clinic - Brecksville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 4 |
What the finished NCT04669561 record still lists
NCT04669561 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 93-participant average among 41 other Dry Eye trials with a reported enrollment target.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Lifitegrast 5% Ophthalmic Solution is the first listed.
NCT04669561 reports a single indexed study location in California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04669561 about?
NCT04669561 is a clinical study titled "The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study". In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.
What is the current status of trial NCT04669561?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-03-17. Estimated completion is 2021-10-08.
What conditions does trial NCT04669561 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT04669561?
The interventions under investigation include: Lifitegrast 5% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04669561?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669561 being conducted?
This trial has 3 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04669561's enrollment target sits among peer trials
100 13th of 41 higher than 29 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI